Leukemia, B-cell Clinical Trial
Official title:
Safety and Effectiveness of Donor γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Safety and Effectiveness of Donor γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
γδT cells belong to the innate immune system and have a powerful anti-tumor effect. Leukemia patients transplanted with allogeneic hematopoietic stem cells have an important role in controlling leukemia recurrence. Although adoptive immunotherapy using in vitro expanded γδT cells has achieved significant results in patients with solid tumors, infusion of donor γδT cells in leukemia patients undergoing allogeneic hematopoietic stem cell transplantation to prevent leukemia recurrence has not been reported. . This clinical study intends to initially observe the safety and effectiveness of donor γδT cell infusion to prevent recurrence/refractory leukemia salvage allogeneic hematopoietic stem cell transplantation to further improve the transplantation effect of these patients ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT03605589 -
Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma
|
Phase 1 | |
| Enrolling by invitation |
NCT02473757 -
Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
|
||
| Recruiting |
NCT04649983 -
CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03614858 -
CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
|
Phase 1/Phase 2 | |
| Terminated |
NCT02848911 -
Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL
|
Phase 1 | |
| Terminated |
NCT02518750 -
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
|
Phase 2 | |
| Enrolling by invitation |
NCT03229200 -
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
|
Phase 4 | |
| Not yet recruiting |
NCT03599375 -
Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia
|
Phase 1 | |
| Recruiting |
NCT02813837 -
Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies
|
N/A | |
| Recruiting |
NCT04271410 -
CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03598179 -
XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects
|
Phase 2 | |
| Recruiting |
NCT05254743 -
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
|
Phase 3 | |
| Recruiting |
NCT05010564 -
Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)
|
Phase 1 | |
| Recruiting |
NCT03564977 -
CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation
|
N/A | |
| Recruiting |
NCT05362773 -
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT02672501 -
A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06209671 -
INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia
|
Phase 1 | |
| Recruiting |
NCT03564470 -
Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04271800 -
Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
|
Phase 1/Phase 2 | |
| Completed |
NCT01087294 -
Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation
|
Phase 1 |